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Background/Introduction
Long-term prognosis after coronary artery bypass graft-
ing (CABG) is related to the patency of coronary grafts,
and pathogenesis of graft closure is linked to platelet
aggregation. We analyzed the effect on late outcomes of
postoperative dual antiplatelet treatment (DAT), main-
tained during the first year, compared to single antiplate-
let treatment (SAT).
Aims/Objectives
A) Primary: Evaluation of adverse cardiovascular events:
Hospital admission for acute coronary syndromes (ACS),
unplanned target-vessel revascularization (UTVR), stroke
and death of cardiovascular origin. B) Secondary: Evalua-
tion of safety: analysis of bleeding events (BE).
Method
Retrospective study including all CABG patients during
the years 2009-2010, with two years of clinical follow-up.
Patients were classified in: A) SAT: daily 100 mg ASA.
B) DAT: daily 100 mg ASA plus daily 75 mg clopidogrel.
Results
The study included 452 patients: 287 SAT (63.5%); 165
DAT (36.5%). 11.9% suffered a primary end-point event;
6.6% ACS; 4.4% UTVR; 1.5% stroke; 3.8% died during fol-
low-up. Safety: 2 (0.4%) suffered a major BE, and 10 (2.2%)
minor BE.
DAT was associated with a reduction of the primary
end-point from 14.6% to 7.3% (p = 0.020). ACS were
reduced from 8.7% to 3.0% (p = 0.020). There were no dif-
ferences in UTVR nor stroke. Mortality during follow-up
was lower in DAT (4.5% versus 2.4%; p = 0.257).
A multivariate Cox proportional-hazards regression was
performed; DAT was independently associated with the
reduction of events (Hazard ratio 0.49; CI 95% 0.249 -
0.968; p = 0.040).
The greatest benefit of DAT was seen after Off-pump
CABG (Hazard ratio 0.395; CI 95% 0.176 - 0.885; p =
0.024) and in diabetic patients (Hazard ratio 0.326; CI 95%
0.124 - 0.854; p = 0.023).
Discussion/Conclusion
DAT is associated with a reduction of late adverse cardi-
ovascular events after CABG, especially in Off-pump
CABG and in diabetic patients. DAT did not increase the
risk of BE.
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